NeuroPace Inc (NPCE)

What is drug-resistant epilepsy and why does it matter?

Epilepsy is a neurological disorder characterised by recurrent seizures. For most patients, anti-seizure medications control seizures effectively, allowing them to lead normal lives. But for roughly one-third of people with epilepsy, medications do not work well enough. These patients have what is called drug-resistant epilepsy—their seizures persist despite trying multiple antiepileptic drugs. They face recurring episodes that disrupt work and school, pose risks of injury, and carry a small but real risk of sudden unexpected nocturnal death in epilepsy (SUDEP). For these patients, alternatives to medication are needed.

Surgery—removing or disconnecting the brain region where seizures originate—is an option for some patients, but not all. The seizure focus may be in a critical brain area, making surgical removal risky. Or imaging may not pinpoint a single, focal source; seizures may arise from multiple sites or a distributed network. For patients in these situations, other treatments are the only recourse.

What is responsive neurostimulation and how does it work?

NeuroPace’s core product is the RNS System—a medical device implanted under the scalp that monitors brain electrical activity and delivers targeted electrical stimulation when it detects abnormal patterns that signal the onset of a seizure. The system functions as a closed-loop intervention: it does not deliver constant stimulation but responds to the brain’s own signals. When the device detects the early electrical signature of an emerging seizure, it delivers a brief, precise pulse of stimulation to interrupt the seizure before it starts or to stop it if it has already begun.

The appeal is clear. The patient does not need to take daily medications, does not face drug side effects, and carries a small implanted device that works continuously. The device is programmable, so clinicians can adjust stimulation parameters as needed. And because the stimulation is responsive—triggered only when needed—it may be less disruptive than constant stimulation approaches.

How did NeuroPace get here?

NeuroPace was founded in 1997 by neuroscientists and entrepreneurs who recognised that responsive neurostimulation could be a solution for drug-resistant epilepsy. For years, the company developed the technology, conducted clinical trials, and worked through the regulatory process with the FDA. The pivotal trial demonstrated that patients receiving RNS experienced a significant reduction in seizure frequency compared to patients who did not have the device active. Based on this evidence, the FDA approved the RNS System for use in drug-resistant epilepsy in 2018. It was a milestone moment: the first responsive neurostimulation system approved for this indication in the United States.

After approval, NeuroPace began commercialising the system, working with epilepsy centres and neurosurgeons to implant devices in eligible patients. Early uptake was modest, as awareness of the technology was limited, and the procedure requires surgical implantation by a skilled neurosurgeon. But over several years, awareness has grown, more surgeons have been trained in the implant procedure, and patient demand has increased.

How does NeuroPace make money?

The company’s revenue model has two parts. First, it receives payment for each device implanted. The implantation is a surgical procedure performed at a hospital, and NeuroPace receives reimbursement from insurance companies or government health programmes for the device and the associated implantation costs. This upfront revenue is substantial for each implant.

Second, the company earns recurring revenue from patient monitoring and device management. After implantation, patients return for periodic clinic visits where their device is adjusted and their data are reviewed. NeuroPace provides software and services that allow clinicians to monitor the patient’s device wirelessly and adjust stimulation parameters. Patients may also purchase subscription services for at-home monitoring and support. This recurring revenue stream is the long-tail economics of the device business: each implanted patient is a revenue generator for years or decades.

What makes the business challenging?

NeuroPace faces several headwinds. First, the procedure requires specialised expertise. A neurosurgeon must place the device electrodes precisely in the brain region where seizures originate. This limits the number of centres and surgeons capable of performing implants, which slows adoption. NeuroPace must invest in training surgeons and building relationships with epilepsy programmes, a slow process.

Second, reimbursement is not guaranteed. Insurance companies must decide to cover the RNS System and set reimbursement rates. NeuroPace must demonstrate to payers that the device is cost-effective—that the benefit to patients (fewer seizures, improved quality of life) justifies the cost of the device and implantation procedure. If coverage is limited or rates are low, implant volume suffers.

Third, the patient population is finite. Drug-resistant epilepsy affects millions globally, but eligible patients—those for whom surgery is unsuitable or has failed and who meet clinical criteria for RNS—are a subset. NeuroPace must grow by increasing the proportion of eligible patients who know about the device and pursue implantation, by expanding indications to new patient populations, or by entering new geographies. Market saturation in developed countries is a long-term ceiling on growth.

What is changing in neuromodulation?

The broader field of neurostimulation is advancing. New devices using different mechanisms are being studied for epilepsy and other neurological conditions. Closed-loop technologies like NeuroPace’s are becoming more sophisticated, with better seizure detection algorithms and more targeted stimulation. And there is growing recognition in neurology that for certain intractable conditions, device-based interventions may be preferable to lifelong medications.

NeuroPace is also exploring whether the RNS System can be effective for other conditions beyond epilepsy—potentially depression, chronic pain, or other neurological disorders. If the underlying technology can address multiple markets, the company has a path to grow beyond its current epilepsy focus. Conversely, if competitors develop alternative neurostimulation approaches that are less invasive or more effective, NeuroPace’s position could be challenged.

How to evaluate NeuroPace as an investment

The 10-K filing (SEC CIK 0001528287) details the company’s product portfolio, the reimbursement environment by region, and the number of implants performed in each quarter. Quarterly earnings calls reveal whether implant volume is accelerating, whether gross margins are expanding as the company scales, and what management’s outlook is for future adoption and geographic expansion.

Key metrics to follow: How many RNS devices are being implanted per quarter, and is that number growing? What is the reimbursement rate, and is it stable or under pressure? Are insurance companies expanding coverage, or are there restrictions? Is the company gaining surgeon support and expanding the number of trained implant centres? Are there updates on potential new indications or geographies? What is the installed base of RNS patients, and how much recurring revenue does each patient generate? For a medical device company like NeuroPace, these operational indicators are far more revealing than accounting metrics alone.